PuSH - Publikationsserver des Helmholtz Zentrums München

Van Eeckhoutte, H.P.* ; Donovan, C.* ; Kim, R.Y.* ; Conlon, T.M. ; Ansari, M. ; Khan, H.* ; Jayaraman, R.* ; Hansbro, N.G.* ; Dondelinger, Y.* ; Delanghe, T.* ; Beal, A.M.* ; Geddes, B.* ; Bertin, J.* ; Berghe, T.V.* ; De Volder, J.* ; Maes, T.* ; Vandenabeele, P.* ; Vanaudenaerde, B.M.* ; Deforce, D.* ; Škevin, S.* ; Van Nieuwerburgh, F.* ; Verhamme, F.M.* ; Joos, G.F.* ; Idrees, S.* ; Schiller, H. B. ; Yildirim, A.Ö. ; Faiz, A.* ; Bertrand, M.J.M.* ; Brusselle, G.G.* ; Hansbro, P.M.* ; Bracke, K.R.*

RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD.

Eur. Respir. J. 61:2201506 (2022)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
RATIONALE: Receptor-interacting protein kinase 1 (RIPK1) is a key mediator of regulated cell death (including apoptosis and necroptosis) and inflammation, both drivers of chronic obstructive pulmonary disease (COPD) pathogenesis. OBJECTIVE: We aimed to define the contribution of RIPK1 kinase-dependent cell death and inflammation in the pathogenesis of COPD. METHODS: We assessed RIPK1 expression in single-cell RNA-sequencing data from human and mouse lungs and validated RIPK1 levels in lung tissue of COPD patients via immunohistochemistry. Next, we assessed the consequences of genetic and pharmacological inhibition of RIPK1 kinase activity in experimental COPD, using Ripk1S25D /S25D kinase deficient mice and the RIPK1 kinase inhibitor GSK'547. MEASUREMENTS AND MAIN RESULTS: RIPK1 expression increased in alveolar type I (AT1), AT2, ciliated and neuroendocrine cells in human COPD. RIPK1 protein levels were significantly increased in airway epithelium of COPD patients, compared to never smokers and smokers without airflow limitation. In mice, exposure to cigarette smoke (CS) increased Ripk1 expression similarly in AT2 cells, and further in alveolar macrophages and T cells. Genetic and/or pharmacological inhibition of RIPK1 kinase activity significantly attenuated airway inflammation upon acute and subacute CS-exposure, as well as airway remodeling, emphysema and apoptotic and necroptotic cell death upon chronic CS-exposure. Similarly, pharmacological RIPK1 kinase inhibition significantly attenuated elastase-induced emphysema and lung function decline. Finally, RNA-sequencing on lung tissue of CS-exposed mice revealed downregulation of cell death and inflammatory pathways upon pharmacological RIPK1 kinase inhibition. CONCLUSIONS: RIPK1 kinase inhibition is protective in experimental models of COPD and may represent a novel promising therapeutic approach.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Obstructive Pulmonary-disease; Virus-infection; Necroptosis; Proliferation; Expression; Apoptosis; Release; Package; Life
ISSN (print) / ISBN 0903-1936
e-ISSN 1399-3003
Zeitschrift European Respiratory Journal
Quellenangaben Band: 61, Heft: 4, Seiten: , Artikelnummer: 2201506 Supplement: ,
Verlag European Respiratory Society
Verlagsort Sheffield
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Lung Biology (LHI)
Lung Health and Immunity (LHI)
Institute of Computational Biology (ICB)
Förderungen Fund for Scientific Research in Flanders (FWO Vlaanderen)
EOS MODEL-IDI
EOS-CD-INFLADIS
FWO research grants
Methusalem
Concerted Research Action of Ghent University
Foundation against Cancer
CRIG
GIGG consortia
VIB
National Health and Medical Research Council (NHMRC) of Australia
University of Technology Sydney
EOS contract